undamentalytics Newsletter
Sign in

Invo Fertility, Inc. (IVF) stock

Add to watchlist

Add holding +

NASDAQ: IVF Nasdaq Health Care Equipment Next results ~November 16, 2026

C+ Fundamentals grade

Invo Fertility, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$3.2

Price-to-sales vs peers

Base case. Range ~$3.2–$16. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Invo Fertility, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades

Value diary

Our note on each quarter Invo Fertility files

Where Invo Fertility stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $8m, up 13.8% on a year earlier, faster than the 9.5% growth a quarter earlier. Free-cash-flow margin rose to -63.3% from -100.1% a year earlier. Operating margin widened to -78.7% from -112.6%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 5 financial-health checks.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Invo Fertility, Inc.'s trailing-twelve-month revenue grew 13.8% year on year, with a free-cash-flow margin of -63.3%. Where it stands out: days sales outstanding of 12 days ranks 3 of 118 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 28.0% while net income grew 73.7%: a 46pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 4.3 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 33.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 16 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -78.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -63.3% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 64.3% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 26.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 163% and a beta of 1.3 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$2.38 against an average estimate of -$22.40: beat by 89.4%
Revenue
$2m, up 16.7% on a year earlier
Share reaction
+47.1% in the first session after the results on August 17, 2026, against -1.1% for the S&P 500

Invo Fertility's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.2%
  • 1 week-19.7%
  • 1 month-46.5%
  • This year-97.0%
  • 1 year-99.5%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$7.5M
Operating margin
-78.7%
Net margin
-92.3%

Growth

Revenue growth
+13.8%
Change in growth rate
+4.3 pts

Cash

Free cash flow (TTM)
-$4.8M
FCF margin
-63.3%

Earnings

Last results
August 17, 2026
Next results (est.)
November 16, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Invo Fertility, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Invo Fertility, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10%: the 10-year Treasury yield (4.9%) plus a beta of 1.13 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$3.2 ~$3.8–$16 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$3.2 ~$3.2–$16 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Invo Fertility, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025
Share price$11096064.00$12275712.00$1563033.62$93312.00$18662.40$60.24
Market value$353m$378m$55m$8m$1m$176329
+ Net debt (− = net cash)−$9m−$6m$0$0$0$0
Enterprise value$343m$372m$55m$8m$1m$176329
Multiples
Price / sales n/m90.8x66.7x2.6x0.2x0.0x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

34 /100

Weak moat

How hard Invo Fertility's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -179.6% of total assets over 10 years.

  • Pricing power 12 / 20

    Gross margin has been a median 80.7%, moving by 19.5 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -268.6%; its worst year was -816.7%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 6 years, at a median -80.3% of revenue.

  • Discipline 10 / 20

    The diluted share count fell 88.5% over five years; stock-based pay has been a median 64.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2227.20 — $10m +52%
Next −$768.00 +66% $16m +58%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +373.5% on 90 days ago. In the last 30 days, 1 analyst raised Invo Fertility, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Invo Fertility, Inc., last 90 days
−$3000.00 −$2000.00 −$1000.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$470.40 Current fiscal year, 60 days ago: −$470.40 Current fiscal year, 30 days ago: −$470.40 Current fiscal year, 7 days ago: −$470.40 Current fiscal year, Now: −$2227.20 −$2227.20 Next fiscal year, 90 days ago: −$883.20 Next fiscal year, 60 days ago: −$883.20 Next fiscal year, 30 days ago: −$883.20 Next fiscal year, 7 days ago: −$883.20 Next fiscal year, Now: −$768.00 −$768.00

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$470.40−$883.20
60 days ago −$470.40−$883.20
30 days ago −$470.40−$883.20
7 days ago −$470.40−$883.20
Now −$2227.20−$768.00

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$22.40 −$2.38 +89.4%
Mar 2026 −$40.00 −$13.45 +66.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 17, 2026

No numeric guidance in Invo Fertility, Inc.'s latest earnings release (filed August 17, 2026). Some companies give their outlook only on the earnings call.

Positioning

Short interest
0.6%
of tradable shares
Days to cover
0.19
at average volume
Short interest, 1 month
−86%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
—
of shares
Employees
40
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −99.5%

$346.24 on October 31, 2025 to $1.83

ThenNowEffect
Revenue (last 12 months) $7m $8m +13.8%
P/S multiple 34.1x 0.2x −99.5%
Share count 1m 1m −2.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IVF+11%−87%−94%−80%−100%−97%
Industry peers (median)−9%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IVF50%25%33%33%8%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IVF−69%−90%−98%−84%−100%−98%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2020: 100% from November 3, 2020 to November 2, 2026. Getting back needed a 3057795534% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.83 – $364.16
From 52-week high
−99.5%
vs 50-day average
−44.5%
vs 200-day average
−80.4%
Volatility (1 year)
163%
Beta vs S&P 500
1.27

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±21.2%
After a week
4 up, 8 down
typical move ±23.1%
After a month
2 up, 10 down
typical move ±28.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 17, 2026 +47.1% −1.1% +6.0% −4.0%
June 22, 2026 −8.7% −1.8% +32.7% −30.7%
June 2, 2026 +15.6% −0.6% −4.8% +10.2%
November 17, 2025 −10.6% −1.8% −33.2% −72.4%
August 15, 2025 −19.4% −0.3% −36.0% −45.7%
May 21, 2025 −18.3% −1.6% −22.0% −50.9%
April 30, 2025 +16.8% +0.7% +29.2% +5.0%
August 14, 2024 −8.1% +2.0% −11.1% −23.8%
May 15, 2024 −10.7% +1.0% −18.4% −8.0%
April 16, 2024 −20.9% −0.8% −43.5% −53.5%
November 13, 2023 +64.9% +1.8% +31.3% −8.4%
August 14, 2023 −13.1% −0.6% −8.5% −34.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Invo Fertility, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Invo Fertility, Inc.
$0 $2M $4M $6M $8M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.9M Revenue (TTM), FY23 Q4: $3M Revenue (TTM), FY24 Q1: $4.2M Revenue (TTM), FY24 Q2: $5.8M Revenue (TTM), FY24 Q3: $6.2M Revenue (TTM), FY24 Q4: $6.5M Revenue (TTM), FY25 Q1: $6.6M Revenue (TTM), FY25 Q2: $6.6M Revenue (TTM), FY25 Q3: $6.9M Revenue (TTM), FY25 Q4: $6.8M Revenue (TTM), FY26 Q1: $7.2M Revenue (TTM), FY26 Q2: $7.5M $7.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.9M
FY23 Q4 $3M
FY24 Q1 $4.2M
FY24 Q2 $5.8M
FY24 Q3 $6.2M
FY24 Q4 $6.5M
FY25 Q1 $6.6M
FY25 Q2 $6.6M
FY25 Q3 $6.9M
FY25 Q4 $6.8M
FY26 Q1 $7.2M
FY26 Q2 $7.5M
Revenue growth, TTM YoY Invo Fertility, Inc.
-200% 0% 200% 400% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -46.6% Revenue growth, TTM YoY, FY23 Q4: 267.4% Revenue growth, TTM YoY, FY24 Q1: 321.7% Revenue growth, TTM YoY, FY24 Q2: 390.0% Revenue growth, TTM YoY, FY24 Q3: 224.9% Revenue growth, TTM YoY, FY24 Q4: 116.3% Revenue growth, TTM YoY, FY25 Q1: 55.2% Revenue growth, TTM YoY, FY25 Q2: 14.7% Revenue growth, TTM YoY, FY25 Q3: 11.5% Revenue growth, TTM YoY, FY25 Q4: 4.7% Revenue growth, TTM YoY, FY26 Q1: 9.5% Revenue growth, TTM YoY, FY26 Q2: 13.8% 13.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -46.6%
FY23 Q4 267.4%
FY24 Q1 321.7%
FY24 Q2 390.0%
FY24 Q3 224.9%
FY24 Q4 116.3%
FY25 Q1 55.2%
FY25 Q2 14.7%
FY25 Q3 11.5%
FY25 Q4 4.7%
FY26 Q1 9.5%
FY26 Q2 13.8%
Operating margin (TTM) Invo Fertility, Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -416.1% Operating margin (TTM), FY23 Q4: -224.0% Operating margin (TTM), FY24 Q1: -140.5% Operating margin (TTM), FY24 Q2: -99.8% Operating margin (TTM), FY24 Q3: -99.1% Operating margin (TTM), FY24 Q4: -101.5% Operating margin (TTM), FY25 Q1: -95.8% Operating margin (TTM), FY25 Q2: -112.6% Operating margin (TTM), FY25 Q3: -112.2% Operating margin (TTM), FY25 Q4: -105.8% Operating margin (TTM), FY26 Q1: -105.7% Operating margin (TTM), FY26 Q2: -78.7% -78.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -416.1%
FY23 Q4 -224.0%
FY24 Q1 -140.5%
FY24 Q2 -99.8%
FY24 Q3 -99.1%
FY24 Q4 -101.5%
FY25 Q1 -95.8%
FY25 Q2 -112.6%
FY25 Q3 -112.2%
FY25 Q4 -105.8%
FY26 Q1 -105.7%
FY26 Q2 -78.7%
FCF margin (TTM) Invo Fertility, Inc.
-1000% -500% 0% FY20 Q4 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY20 Q4: -465.1% FCF margin (TTM), FY22 Q3: -189.1% FCF margin (TTM), FY22 Q4: -804.4% FCF margin (TTM), FY24 Q2: -68.7% FCF margin (TTM), FY24 Q3: -52.2% FCF margin (TTM), FY24 Q4: -48.3% FCF margin (TTM), FY25 Q1: -97.2% FCF margin (TTM), FY25 Q2: -100.1% FCF margin (TTM), FY25 Q3: -111.9% FCF margin (TTM), FY25 Q4: -103.2% FCF margin (TTM), FY26 Q1: -74.6% FCF margin (TTM), FY26 Q2: -63.3% -63.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY20 Q4 -465.1%
FY22 Q3 -189.1%
FY22 Q4 -804.4%
FY24 Q2 -68.7%
FY24 Q3 -52.2%
FY24 Q4 -48.3%
FY25 Q1 -97.2%
FY25 Q2 -100.1%
FY25 Q3 -111.9%
FY25 Q4 -103.2%
FY26 Q1 -74.6%
FY26 Q2 -63.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 0 0 0 1 1 4 1 3 7 7 8
Gross profit 0 0 0 0 0 0 0 0 1 1 4 0 1 3 7 —
EBITDA −1 −1 −1 −2 −1 −2 −1 −3 −2 −6 −5 −11 −7 −6 −7 −5
Operating income −1 −1 −1 −2 −1 −2 −1 −3 −2 −6 −5 −11 −7 −7 −7 −6
Net income −1 −1 −1 −2 −5 −2 −1 −3 −2 −8 −7 −11 −8 −9 −23 −7
Diluted EPS −$1727.93 −$7.20 −$7.20 −$14.40 −$6911.72 −$14.40 $0.00 −$14.40 −$77756.83 −$1094.36 −$907.16 −$310508.96 −$97008.85 −$151304.48 −$8585.51 —
Growth (year on year)
Revenue — −21.2% −52.0% −38.7% −29.5% +335.5% +454.3% +75.2% +199.4% −29.9% +301.1% −80.2% +267.4% +116.3% +4.7% +13.8%
Margins
Gross margin 74.9% 63.0% 60.9% 53.7% 33.2% 70.3% 81.6% 81.7% 90.6% 91.4% 96.5% 59.7% 34.7% 43.1% 99.6% —
EBITDA margin −953.5% −959.2% <−999% <−999% <−999% <−999% −226.0% −531.8% −120.1% −530.5% −124.7% <−999% −217.4% −87.4% −95.9% −71.3%
Operating margin −983.4% −979.7% <−999% <−999% <−999% <−999% −227.0% −532.8% −120.8% −531.7% −125.4% <−999% −224.0% −101.5% −105.8% −78.7%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −248.9% −622.2% −146.4% −804.7% −160.0% <−999% −266.0% −141.7% −340.9% −92.3%
Free-cash-flow margin — — — — <−999% −667.2% −64.2% −136.0% 88.2% −465.1% −154.9% −804.4% −172.1% −48.3% −103.2% −63.3%
Cash flow
Cash from operations −0 −0 −0 −0 −0 −0 −0 −1 1 −5 −6 −7 −5 −3 −7 −5
Capital spending — — — — 0 0 0 0 0 0 0 0 0 0 0 0
Free cash flow — — — — −0 −0 −0 −1 1 −5 −6 −7 −5 −3 −7 −5
Stock-based pay — — — — — — — 0 0 1 2 2 — — 0 —
Free cash flow after stock pay — — — — — — — −1 1 −6 −8 −8 — — −7 —
Balance sheet
Cash 0 0 0 0 0 0 0 0 1 10 6 — — — — —
Total debt 0 0 0 0 0 0 0 0 0 1 — 0 1 7 2 2
Net debt (negative = net cash) 0 0 0 0 −0 −0 0 0 −1 −9 −6 — — — — —
Diluted shares — — — — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $26m
Short-term assets $5mLonger-term assets $21m
What it owes, and who funded it · $26m
Short-term liabilities $7mLonger-term liabilities $3mShareholders' equity $16m
  • Short-term assets cover short-term liabilities $5m of assets due within a year against $7m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5m short-term assets against $3m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Debt is 10% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$5m of operating cash flow against $2m of debt.
  • Operating profit covers interest at least five times over Operating income of −$6m against $1m of interest.

From Invo Fertility, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
4.0%
of revenue
Sales & admin spending
106.5%
of revenue
Days sales outstanding
12 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated IVF XAIR NNNN NUWE MLSS NMTC Median
Revenue, last 12 months $8m $8m $9m $9m $9m $9m $99m
Revenue growth, last 12 months 13.8% 60.7% 5.6% 8.4% 3.7% 42.8% 9.2%
Revenue growth, 3-year average 85.6% 122.7% — 2.8% −1.9% 94.9% 13.5%
Revenue growth, latest quarter 16.7% 0.5% — 14.1% 22.3% 16.3% 10.2%
Gross margin 53.6% 4.2% 87.2% 69.7% 70.2% 55.6% 61.2%
Operating margin −78.7% −364.8% 66.7% −142.9% −43.6% −83.4% −8.5%
Operating margin, 3-year average −97.0% <−999% — −138.4% −66.8% −160.3% −17.9%
Net margin −92.3% −435.7% 74.1% −125.6% −44.0% −78.6% −12.0%
Cash from operations / revenue −63.3% −241.5% −77.9% −138.3% −6.8% −74.5% −1.9%
Free-cash-flow margin −63.3% −255.0% — −139.7% −7.0% −75.6% −3.9%
Free-cash-flow margin, 3-year average −77.4% <−999% — −126.7% −53.1% −142.5% −7.0%
Stock pay / revenue 64.3% 61.7% — 1.0% 10.3% 14.9% 6.1%
Change in share count 26.6% −99.0% 3.3% 5.4% 5.9% 41.1% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 13.8% 9.1% 52 of 129
Change in growth rate Growth +4.3pp -0.6pp 25 of 129
Gross margin Profitability 53.6% 61.9% 83 of 123
Operating margin Profitability -78.7% -8.3% 100 of 132
Net margin Profitability -92.3% -12.0% 103 of 133
Free-cash-flow margin Cash generation -63.3% -3.4% 98 of 128
Long-term debt as % of assets Balance sheet 2.0% 24.2% 15 of 87
Days sales outstanding Balance sheet 12 days 57 days 3 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Fertility Clinic Services $6.7M 97.9% ▲ 4.2%
Invocell Device $147,193 2.1% ▲ 33.1%
Products and services
Line of business Revenue Share YoY
Revenue From External Customers $6.8M 99.6% ▲ 4.7%
Clinic Revenue $6.7M 98.2% ▲ 4.2%
Products $120,193 1.8% ▲ 47.4%
Inter Segment Revenue $27,000 0.4% ▼ 6.9%

From Invo Fertility, Inc.'s 10-K filed June 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

13F filings for June 30, 2026
Reported value
$248,728
Institutions reporting
9
Shares held vs prior quarter
▼ 31.8%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Virtu Financial LLC $120,000 63K 48.2% New
Scientech Research LLC $61,442 32K 24.7% New
Stonex Group Inc. $29,822 16K 12.0% New
Susquehanna International Group, LLP $21,780 11K 8.8% New
Tower Research Capital LLC (TRC) $15,494 8K 6.2% New
Sbi Securities Co., Ltd. $101 0K 0.0% ▲ 1666.7%
Caitong International Asset Management Co., Ltd $72 0K 0.0% New
Integrated Wealth Concepts LLC $15 0K 0.0% New
Danske Bank A/S $2 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Invo Fertility, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $6 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $6 net selling
Insider Date Trade Shares Price Value
Szot Matthew K Director December 3, 2025 Sell 4 $1.52 $6

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 16, 2026 estimated from the company's past filing pattern, not announced

  • August 17, 2026
  • June 22, 2026
  • June 2, 2026
  • November 17, 2025
  • August 15, 2025
  • May 21, 2025

Recent SEC filings

Data status

When each part of this page on Invo Fertility, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Invo Fertility, Inc. in brief

What does Invo Fertility, Inc. do?
Invo Fertility, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Invo Fertility, Inc.'s stock ticker?
Invo Fertility, Inc. trades under the ticker IVF on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Invo Fertility, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Invo Fertility, Inc. reported revenue of $7.5M, 13.8% higher than a year earlier, according to its SEC filings.
What is Invo Fertility, Inc.'s free cash flow?
Invo Fertility, Inc.'s free-cash-flow margin is -63.3% of revenue over the trailing twelve months, ranking 98 of the 128 health care equipment companies we cover.
Who are Invo Fertility, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Virtu Financial LLC, Scientech Research LLC and Stonex Group Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Invo Fertility, Inc.'s market cap?
On December 31, 2025, Invo Fertility, Inc.'s market capitalisation was about $176,329 and net debt of $0. Market figures come from third-party market data and may be delayed.
How much debt does Invo Fertility, Inc. have?
Invo Fertility, Inc.'s debt-to-equity ratio is 9.9%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Invo Fertility, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Invo Fertility, Inc. are Beyond Air, Inc., Anbio Biotechnology, Nuwellis, Inc., Milestone Scientific Inc. and Neuroone Medical Technologies Corp. The side-by-side comparison below sets their revenue, margins and growth against Invo Fertility, Inc.'s.
Are insiders buying or selling Invo Fertility, Inc. stock?
Over the last 12 months, Invo Fertility, Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Invo Fertility, Inc.'s next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Invo Fertility, Inc. announces its own schedule.